213 related articles for article (PubMed ID: 22013422)
1. Current medical treatments for juvenile idiopathic arthritis.
Ruperto N; Martini A
Front Pharmacol; 2011; 2():60. PubMed ID: 22013422
[TBL] [Abstract][Full Text] [Related]
2. Emerging drugs to treat juvenile idiopathic arthritis.
Ruperto N; Martini A
Expert Opin Emerg Drugs; 2011 Sep; 16(3):493-505. PubMed ID: 21529300
[TBL] [Abstract][Full Text] [Related]
3. Juvenile idiopathic arthritis: state of the art and future perspectives.
Martini A; Lovell DJ
Ann Rheum Dis; 2010 Jul; 69(7):1260-3. PubMed ID: 20525835
[TBL] [Abstract][Full Text] [Related]
4. Toward New Classification Criteria for Juvenile Idiopathic Arthritis: First Steps, Pediatric Rheumatology International Trials Organization International Consensus.
Martini A; Ravelli A; Avcin T; Beresford MW; Burgos-Vargas R; Cuttica R; Ilowite NT; Khubchandani R; Laxer RM; Lovell DJ; Petty RE; Wallace CA; Wulffraat NM; Pistorio A; Ruperto N;
J Rheumatol; 2019 Feb; 46(2):190-197. PubMed ID: 30275259
[TBL] [Abstract][Full Text] [Related]
5. Current Therapeutic Options for the Treatment of Juvenile Idiopathic Arthritis.
Saougou IG; Markatseli TE; Voulgari PV; Drosos AA
Curr Rheumatol Rev; 2021; 17(1):41-57. PubMed ID: 32942977
[TBL] [Abstract][Full Text] [Related]
6. A Comparison of International League of Associations for Rheumatology and Pediatric Rheumatology International Trials Organization Classification Systems for Juvenile Idiopathic Arthritis Among Children in a Canadian Arthritis Cohort.
Lee JJY; Eng SWM; Guzman J; Duffy CM; Tucker LB; Oen K; Yeung RSM; Feldman BM;
Arthritis Rheumatol; 2022 Aug; 74(8):1409-1419. PubMed ID: 35289119
[TBL] [Abstract][Full Text] [Related]
7. Current Validated Clinical and Patient Reported Disease Outcome Measures in Juvenile Idiopathic Arthritis.
Balay-Dustrude E; Shenoi S
Open Access Rheumatol; 2023; 15():189-206. PubMed ID: 37841510
[TBL] [Abstract][Full Text] [Related]
8. [JUVENILE IDIOPATHIC ARTHRITIS].
Bukovac LT; Perica M
Reumatizam; 2016; 63 Suppl 1():53-8. PubMed ID: 29624302
[TBL] [Abstract][Full Text] [Related]
9. Advances from clinical trials in juvenile idiopathic arthritis.
Lovell DJ; Ruperto N; Giannini EH; Martini A
Nat Rev Rheumatol; 2013 Sep; 9(9):557-63. PubMed ID: 23838613
[TBL] [Abstract][Full Text] [Related]
10. [Change of diagnosis and diagnostic category in patients with juvenile idiopathic arthritis within 7 years of follow-up].
Strickler AL; Cifuentes D; Mihovilovic K; Vergara F; Grez M; Rivera V
Rev Chil Pediatr; 2020 Aug; 91(4):521-528. PubMed ID: 33399728
[TBL] [Abstract][Full Text] [Related]
11. Impact of the European paediatric legislation in paediatric rheumatology: past, present and future.
Ruperto N; Vesely R; Saint-Raymond A; Martini A;
Ann Rheum Dis; 2013 Dec; 72(12):1893-6. PubMed ID: 23962457
[TBL] [Abstract][Full Text] [Related]
12. Intravenous Golimumab in Patients with Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis and Subcutaneous Ustekinumab in Patients with Juvenile Psoriatic Arthritis: Extrapolation of Data from Studies in Adults and Adjacent Pediatric Populations.
Leu JH; Shiff NJ; Clark M; Bensley K; Lomax KG; Berezny K; Nelson RM; Zhou H; Xu Z
Paediatr Drugs; 2022 Nov; 24(6):699-714. PubMed ID: 36171515
[TBL] [Abstract][Full Text] [Related]
13. Juvenile idiopathic arthritis: Diagnosis and differential diagnosis.
Kim KH; Kim DS
Korean J Pediatr; 2010 Nov; 53(11):931-5. PubMed ID: 21218014
[TBL] [Abstract][Full Text] [Related]
14. Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT.
Ramanan AV; Dick AD; Jones AP; Hughes DA; McKay A; Rosala-Hallas A; Williamson PR; Hardwick B; Hickey H; Rainford N; Hickey G; Kolamunnage-Dona R; Culeddu G; Plumpton C; Wood E; Compeyrot-Lacassagne S; Woo P; Edelsten C; Beresford MW
Health Technol Assess; 2019 Apr; 23(15):1-140. PubMed ID: 31033434
[TBL] [Abstract][Full Text] [Related]
15. Biologics in juvenile idiopathic arthritis: a narrative review.
Vanoni F; Minoia F; Malattia C
Eur J Pediatr; 2017 Sep; 176(9):1147-1153. PubMed ID: 28725955
[TBL] [Abstract][Full Text] [Related]
16. Familial aggregation of juvenile idiopathic arthritis with other autoimmune diseases: Impact on clinical characteristics, disease activity status and disease damage.
Al-Mayouf SM; Alrasheedi A; Almsellati I; Hashad S; Khawaja K; Abdwani R; AlHashim S; Muzaffer M; Lotfy H; Almutairi N
Int J Rheum Dis; 2021 Aug; 24(8):1080-1085. PubMed ID: 34184820
[TBL] [Abstract][Full Text] [Related]
17. Emerging therapies for juvenile arthritis: agents in early clinical trials.
Rosina S; Giancane G; Ruperto N
Expert Opin Investig Drugs; 2022 Oct; 31(10):1109-1124. PubMed ID: 36066506
[TBL] [Abstract][Full Text] [Related]
18. Summary of AHRQ's Comparative Effectiveness Review of Disease-Modifying Antirheumatic Drugs for Children with Juvenile Idiopathic Arthritis.
McMahan R; Balfe LM; Greene L
J Manag Care Pharm; 2012; 18(1 Suppl B):1-16. PubMed ID: 22376227
[TBL] [Abstract][Full Text] [Related]
19. Performance of rheumatoid arthritis disease activity measures and juvenile arthritis disease activity scores in polyarticular-course juvenile idiopathic arthritis: Analysis of their ability to classify the American College of Rheumatology pediatric measures of response and the preliminary criteria for flare and inactive disease.
Ringold S; Bittner R; Neogi T; Wallace CA; Singer NG
Arthritis Care Res (Hoboken); 2010 Aug; 62(8):1095-102. PubMed ID: 20506561
[TBL] [Abstract][Full Text] [Related]
20. It is time to rethink juvenile idiopathic arthritis classification and nomenclature.
Martini A
Ann Rheum Dis; 2012 Sep; 71(9):1437-9. PubMed ID: 22679300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
